Prospective evaluation of prognostic factors in operable breast cancer by Hawkins, R A et al.
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Prospective evaluation of prognostic factors in operable breast
cancer
Citation for published version:
Hawkins, RA, Tesdale, AL, Killen, ME, Jack, WJ, Chetty, U, Dixon, JM, Hulme, MJ, Prescott, RJ, McIntyre,
MA & Miller, WR 1996, 'Prospective evaluation of prognostic factors in operable breast cancer' British
Journal of Cancer, vol. 74, no. 9, pp. 1469-78.
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Publisher's PDF, also known as Version of record
Published In:
British Journal of Cancer
Publisher Rights Statement:
© 1996 Stockton Press
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 05. Apr. 2019
Briftsh Journal of Cancer (1996) 74, 1469-1478
© 1996 Stockton Press All rights reserved 0007-0920/96 $12.00 o
Prospective evaluation of prognostic factors in operable breast cancer
RA Hawkins1, AL Tesdalel, ME Killen', WJL Jack2, U Chetty3, JM Dixon3, MJ Hulme2,
RJ Prescott4, MA McIntyre5 and WR Miller2
'University Department of Surgery, Royal Infirmary NHS Trust, Edinburgh EH3 9YW; 2University Department of Oncology and
ICRF Laboratories, Western General Hospital NHS Trust, Edinburgh EH4 2XU; 3Edinburgh Breast Unit, Western General
Hospital NHS Trust, Edinburgh EH4 2XU; 4Medical Statistics Unit, Public Health Sciences, The University Medical School,
Edinburgh EH8 9AG; SDepartment of Pathology, Western General Hospital NHS Trust, Edinburgh EH4 2XU.
Summary In 215 patients with operable breast cancer (TI -T3, NO- 1, MO) and no other or previous cancer,
presenting to a single breast unit, sufficient tumour was available for the prospective determination of four
putative biochemical markers of prognosis: oestrogen receptor (ER) activity, cathepsin D (cath D), epidermal
growth factor receptor (EGFR) activity and cyclic AMP-binding proteins (c-AMP-b). There were significant
inter-relationships between ER and EGFR (r= -0.26), c-AMP-b and cath D (r= + 0.32) and ER and
c-AMP-b (r= +0.14). After follow-up (median 36.2 months), a total of 55 recurrences (18 locoregional only)
and 35 deaths were recorded. By univariate analysis, up to 10 of 18 biochemical, clinical and histopathological
variables of potential prognostic value were significantly related to disease-free interval or death, but by
multivariate analysis only oestrogen receptor concentration and node status contributed significantly to risk of
both distant recurrence/death; in addition, tumour size made a small contribution to the risk for a distant
recurrence only. Only two parameters, tumour grade and ER concentration, were significantly related to risk of
locoregional recurrence by univariate analysis, but by multivariate analysis, only tumour grade was important.
It is concluded that tumour ER concentration, axillary nodal status and tumour grade remain as the most
important prognostic factors in the early years after presentation of operable breast cancer, with a minor
influence of tumour size. At this time, the prognostic significance of quantitative measurements of ER
concentration, carefully controlled for the quality of both assay and tumour specimen, is probably greater than
is generally appreciated. We have yet to identify other factors, which add significantly to the short-term
prognostic value of these key features.
Keywords: oestrogen receptor; cathepsin D; cyclic AMP-binding; epidermal growth factor receptor; operable
breast cancer
Despite the existence of a large number of molecules which
have been reported to be of value in gauging prognosis, it
remains difficult to predict outcome accurately in 'early'
(operable) breast cancer (Osborne, 1992) and different studies
of prognosis have yielded widely differing results (Hawkins,
1993). We have selected four putative biochemical indices of
prognosis and evaluated them in a prospective study. The
putative markers chosen were the oestrogen receptor (ER),
the epidermal growth factor receptor (EGFR), cathepsin D
(cath D) and cyclic AMP-binding protein(s) (c-AMP-b).
The oestrogen receptor, a nuclear protein (Mr 66 kDa) has
been shown to relate to both endocrine sensitivity (Jensen,
1975) and prognosis in multiple studies, including our own
previous work (Humeniuk et al., 1982; Hawkins et al., 1987a,
1991), although some consider that it is only of prognostic
significance in the early years after treatment (e.g. Saez et al.,
1983). The receptor for epidermal growth factor is a
membrane protein (Mr 180 kDa), which has been reported
to be a sign of bad prognosis, again in multiple studies
(Sainsbury et al., 1987; Gasparini et al., 1992). The
proteolytic enzyme, cathepsin D (Mr 52 kDa), has been
suggested to be involved in metastasis formation and
reported in several studies also to be a sign of bad prognosis
when present in high levels (for a review see Rochefort,
1990). Lastly, work in our own laboratories and elsewhere
has demonstrated that high levels of cyclic AMP-binding
protein(s), the regulatory subunits of the enzyme protein
kinase A, represent another sign of poor prognosis, in both
retrospective (Miller et al., 1990) and prospective (Miller et
al., 1993) studies.
In this paper, we report our findings for these markers and
for patient outcome in a group of 215 women with operable
breast cancer, treated within a single clinical unit.
Methods
During the period 1 March 1990 to 1 October 1991,
approximately 650 new breast cancer patients were referred
to the Edinburgh Breast Unit. Of those with operable disease
(TI-3, NO-1, MO), 215 were included in this study.
Excluded were patients with previous malignancies (breast
or other sites), bilateral disease or purely non-invasive
cancers (Tis). Also excluded were cases where the specimen
contained inadequate tumour (< 10% tumour in a section cut
from the face of the specimen used for biochemistry) or
where the specimen was too small to permit all four
biochemical assays to be performed. Of the cases excluded
for these reasons, the major group was that of the smaller
tumours (TI, approximately one-third of all the cases).
The histopathology of the 215 cases was reviewed
retrospectively by one of us (MMcI) from both the section
cut from the tissue block used for biochemistry and the
original pathology report. Pathological tumour size, histo-
pathological grade (Bloom and Richardson, 1957) and
histopathological tumour type were recorded. For analytical
purposes, the tumour type was categorised in order of
anticipated prognostic significance (based on Dixon et al.,
1985 and Fisher et al., 1993) as (1) carcinoma in
situ+microinvasion, n=4; (2) special type (tubular, tubular
variants, mucoid, papillary, cribriform or medullary), n = 18;
(3) lobular or lobular variants, n= 23; or (4) invasive ductal
carcinoma of no special type, n = 168. (For two tumours this
information was not available).
Patients were treated surgically by: (1) conservation
(tumours < 4 cm, wide local excision plus axillary node
sample or clearance); (2) mastectomy and axillary node
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clearance; (3) wedge biopsy/node biopsy before primary
systemic therapy (chemo- or endocrine) followed by
mastectomy 4-6 months later (tumours >4 cm).
Most patients also received adjuvant therapy after
definitive surgery, either endocrine therapy (e.g. tamoxifen)
or chemotherapy (CMF), depending on factors such as node
status and oestrogen receptor levels. Among the 215 patients,
eight were treated by primary systemic therapy (seven in a
randomised trial, one elderly patient received preoperative
tamoxifen). Of the remainder, all postmenopausal patients
received adjuvant tamoxifen therapy post-operatively, except
for four patients, two of whom received chemotherapy.
Premenopausal, node-negative patients were all given
tamoxifen or no adjuvant therapy, apart from three patients
(all with low ER levels), who received chemotherapy as part
of a randomised trial. Premenopausal, node-positive patients
received adjuvant chemotherapy or underwent ovarian
ablation, apart from one patient (with a high ER level),
who received tamoxifen.
Patients were thus categorised as receiving: (1) no adjuvant
therapy (n= 7); (2) adjuvant chemotherapy (n= 33); (3)
adjuvant endocrine therapy (n = 167); (4) primary chemother-
apy (n = 4); or (5) primary endocrine therapy (n = 4). Those
who had conservation surgery received post-operative radio-
therapy.
For the purpose of data analysis, patients were classified
as: (1) premenopausal (last period < 12 months before
surgery and those under 50 years, who had had a previous
hysterectomy without bilateral oophorectomy); (2) post-
menopausal (last period > 12 months before surgery, those
of any age who had had a previous bilateral oophorectomy
and those of 50 years or more who had had a hysterectomy
without oophorectomy).
The patients were followed up at 4-6 monthly intervals
and had annual mammography carried out. Those who
received primary systemic therapy were seen more frequently
before their definitive surgery but, thereafter, the follow-up
was as for those treated by initial surgery.
During follow-up (24.8-46.5 months, median 36.2
months), 55 patients had a recurrence (18 locoregional
only) and 35 died (30 from breast cancer). An initial
preliminary analysis was also performed after a median
follow-up of only 16.5 months (range 1-25 months), but the
results are not detailed here because: (1) that follow-up was
very short; and (2) the findings were virtually identical with
those presented here after 3 years.
Determination of oestrogen receptor activity
Oestrogen receptor activity was determined by enzyme
immunoassay (ER-EIA) using the Abbott kit, according to
the manufacturer's instructions. In brief, tissue cytosols were
prepared by homogenisation in Tris-glycerol-monothiogly-
cerol buffer (Hawkins et al., 1981) and centrifugation at
105 000 x g. An aliquot of cytosol was assayed for protein
by the method of Bradford (1976) (see below) so that the
cytosol could be diluted to 1-2 mg protein ml-'. A 100 ,l
sample of each cytosol and the Abbott quality control were
pipetted with diluent into separate wells of a microtitre plate
alongside 200 ,l receptor standards (0, 5, 25, 100 and
250 fmol ml-'). A glass bead, coated with the first anti-ER
antibody, was added to each well, left to bind overnight
(18 h) at 4°C before aspiration, washing and incubation with
a second anti-ER antibody, conjugated to peroxidase, for 1 h
at 37°C. After reaspiration and washing, the beads were
incubated in 300 pl o-phenylenediamine solution for 30 min
at 30°C, the reaction was terminated by the addition of
1.0 ml sulphuric acid solution (1 N) and the yellow colour was
read at 492 nm. From the resulting standard curve, the values
in the unknowns were calculated by interpolation, corrected
for the dilution and expressed as fmol mg-' protein. Three
additional quality control samples (two uterine tissues and
one pool of breast cancer cytosol) were processed with each
assay.
Although initially (Hawkins et al., 1987b) this assay
yielded values similar to those found by the classical
radioligand-binding method, subsequently, the assay chan-
ged and now yields higher values (Cren et al., 1991). The
assay sensitivity, calculated according to Brown et al. (1957)
is approximately 5 fmol mg-1 protein (derived from a mean
blank of 2.36+s.d. 1.81, n=9, measured on serum albumin
solution/human plasma).
By this assay, the ER concentrations found in 'normal
breast' (taken from patients with either no malignancy or
from an area remote from the tumour in a patient with
cancer, this being confirmed by histological examination)
were 9 fmol mg-' protein (median; range 2- 28, n = 8), in
fibroadenomata 31 (median; range 6- 80, n = 10) and in
more complex benign lesions 47 (median; range 6-102,
n=8).
Determination of EGFR
EGFR was determined on the 'membranes' pellet remaining
after high-speed centrifugation of the homogenate used for
ER assay, by modification of a method described previously
(Hawkins et al., 1991). In brief, the pellet ('membranes'/
total particulate fraction of the cell) was resuspended in
Tris - saline to give a final concentration of > 66 mg
tissue ml-1 by gentle hand rehomogenisation with a
glass - glass homogeniser and passed through a coarse
metal sieve.
A sample of 100 pl of resuspended membranes (,>6.6 mg
tissue) was added to each of six tubes for single saturating-
dose (SSD) assay. Three tubes contained 0.22 nM ['251]EGF
(specific activity 157-183 pCi pg-l, NEN) and the remain-
ing three tubes contained 0.22 nM [125I]EGF plus an excess
(300 nM) of non-radioactive EGF. The tubes were mixed
and incubated (total volume 0.4 ml) for 90 min at 26°C
before separation of free and bound EGF by the addition
of 0.5 ml IgG solution (0.5% w/v) and 1.0 ml of
polyethylene glycol (25% v/v), incubation on ice for
15 min and centrifugation. An additional 100 pl aliquot of
membranes was assayed for proteins (Bradford, 1976; see
below).
In our experience, this SSD method measures only high-
affinity sites by comparison with the multidose saturation
method we used previously (Hawkins et al., 1991) [correlation
between the assays: 1 (SSD) = 1.15 x (Scatchard) + 0.72 fmol
mg- protein, Spearman's r = 0.70, n =24 tissues]. In our
hands, the use of higher concentrations of [251I]EGF (1 nM) in
such an assay (Nicholson et al., 1988) yielded measurements
of a mixture of high- and some low-affinity sites.
Portions of human uterine and rat liver membranes (stored
in liquid nitrogen) were also assayed with each batch of
samples as quality controls. Water blanks (n = 3) were
processed with each assay and the mean value was
0.18 fmol per tube for n = 61 assays. This yields a theoretical
sensitivity of 1.43 fmol mg-' membrane protein, assuming a
typical protein content of 0.3 mg per tube, using the method
of Brown et al. (1957).
Using this assay, the mean EGFR concentrations found in
normal breast (n = 8), fibroadenomata (n= 10) and more
complex benign lesions (n = 8) were 1.96 (range 0-5.11), 1.79
(range 0-4.70) and 2.12 (range 0.48-3.32) fmol mg-1
membrane protein respectively.
Determination of cathepsin D
The cytosol remaining after the ER assay was frozen at
-200C for 1
-2 weeks and kept for the assay of cathepsin D.
The thawed cytosol was assayed using the CIS kit, according
to the manufacturer's instructions.
The CIS kit employs the use of two monoclonal antibodies
prepared against sterically remote antigenic sites on the
cathepsin D molecule. The first antibody (Ab,) is coated on
the ELSA tube and the second is radiolabelled with ['1251]
(Ab).
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Each cytosol was diluted with saline to bring the protein
concentration into the range 0.8-1.2 mg ml-'; this was then
further diluted 1/40 and 1/80 with diluent supplied by CIS.
Powders containing known quantities of cathepsin D were
reconstituted with 0.5 ml distilled water approximately 5 min
before use to yield standards in the approximate range 0-
4000 fmol ml-'. A control cytosol was similarly reconsti-
tuted. 125I-labelled monoclonal antibody (300 Ml) was dis-
pensed into each coated ELSA tube.
An aliquot of 50 jl from each standard, control cytosol and
each diluted sample was then dispensed into the appropriately
labelled ELSA tubes and mixed gently. The tubes were
incubated at approximately 20°C for 3 h under gentle agitation.
The cathepsin D molecules present in the standards,
control or samples form a coated Ab,/antigen/iodinated
Ab2 'sandwich' during this incubation period. The unbound
[1251]Ab2 was removed after incubation by a thorough
washing of ELSA tubes by aspiration to 'dryness', washing
with 3 ml 0.3% Tween 20 in distilled water and reaspiration
to 'dryness'. This procedure was repeated twice more. The 1251
bound to the ELSA tube was then measured with a gamma-
counter and from these counts, a standard curve of 1251
bound vs concentration cathepsin D added was produced,
from which the unknown values were interpolated and
expressed as pmol cathepsin D mg-' protein.
Portions of uterine cytosol were also assayed with each
batch of samples, as quality controls.
Using this assay, the average cathepsin D concentrations
found in normal breast (n = 8), fibroadenomata (n =10) and
more complex benign lesions (n = 8) were 9 (range 3- 14), 14
(range 8 -20) and 30 (range 9 -59) pmol mg-' cytosolic
protein respectively.
Determination of cyclic AMP-binding protein(s)
A portion of the tumour biopsy was homogenised and
assayed as described previously by Miller et al. (1985). In
brief, a cytosol was prepared at 0°C by homogenising tumour
in 20 mM Tris buffer (w/v 1: 10) and centrifuging at
105 000 x g for 1 h at 4°C. The resulting cytosol (50 dl)
was incubated with 5'8' [3H] cyclic AMP (100 1l
25 nM) ± varying concentrations of non-radioactive cyclic
AMP for 3 h at room temperature. The protein-bound
fraction of cyclic AMP was separated from the free fraction
by filtration through a Millipore filter, dried and counted in a
micellar scintillator. The results were analysed by Scatchard
(1949) analysis to yield a binding dissociation constant and a
concentration of binding sites. After determination of soluble
protein concentration by the method of Bradford (1976; see
below), the concentration of cyclic AMP binding sites was
expressed as fmol mg-1 soluble protein.
Determination of protein
Protein concentration in either the cytosol or membrane
preparations was analysed by the method of Bradford (1976).
Membrane preparations were dissolved overnight in 2N
sodium hydroxide solution and neutralised with 2N hydro-
chloric acid solution before assay. Dilutions of either
cytosolic preparation or solubilised membrane preparation
were assayed against a mixed protein standard of human
serum albumin and immunoglobulin G (Sigma 540-10) with
Coomassie blue reagent.
Five quality control samples were processed in each assay
and, where the mean value deviated by > 10% from the
expected, the assay was repeated.
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Statistical evaluation of results
The inter-relationships between variables were examined by
calculating Spearman's rank correlation coefficient and the
relationship of each putative factor to prognosis (disease-free
interval or death) was examined by Cox's proportional
hazards regression model in univariate and multivariate
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analyses. In these analyses, a logarithmic transformation was
applied to variables with noticeably skewed distributions.
In addition, for each putative biochemical factor, the
results were divided into quartiles according to their
concentration in the tumour, and curves to indicate the
probability of staying disease-free or of overall survival were
drawn using Kaplan- Meier estimates. Such curves were also
drawn for nodal status (two categories), tumour grade (three
categories) and clinical tumour size (quartiles).
Results
Incidence of detectable activity of the biochemical markers
Using arbitrary 'cut-offs', ER activity was detected in 87%
(level for positivity > 5 fmol mg-' soluble protein; range 5-
902), EGFR activity in 84% (level for positivity
) 0.1 fmol mg-' membrane protein; range 0.1-73) and
cathepsin D (level for positivity > 1 pmol mg-' soluble
protein; range 2-241) and cyclic AMP-binding activity
(level for positivity > 100 fmol mg-I soluble protein; range
481-11, 333), both in 100% of the cases examined.
Inter-relationships between the markers and other variables
When the levels of pairs of biochemical markers were
examined, it was found that there were correlations between
the concentrations of cathepsin D and cyclic AMP-binding
(Spearman's r = + 0.32), cyclic AMP-binding and ER
(Spearman's r = + 0.14) and an inverse correlation between
ER and EGFR activities (Spearman's r = -0.26). These
correlations are illustrated in Figure 1 and summarised
along with those for other variables examined in Table I.
The inter-relationships between all the 18 variables studied
is shown in the form of a correlation matrix (Table I) in
which the (above) correlations between the biochemical
markers are emphasised in bold type.
Although there are too many associations between the 18
variables studied for detailed comment, it is instructive to note
some of these findings. Many of these associations would be
expected; thus, age related to menstrual status, pathological
tumour size to clinical size, node status to tumour size (clinical/
pathological), and the choices of systemic therapy, radio-
therapy and type of surgery are closely inter-related, with the
latter two related to tumour stage, tumour size (clinical/
pathological) and node status, and the former to age and
menstrual status. Equally, the soluble protein content (SPG) of
a tumour extract relates strongly to the protein content of the
membranes (MPG), which is prepared from the same tumour,
but both relate strongly (r>0.4, P<,0.0001) to the tumour
grade. Tumour grade related significantly to many features:
patient's age, tumour stage, clinical or pathological tumour
size, node status, tumour type, the levels of all of the four
biochemical markers, type of systemic therapy and to the
weight of tissue (TW) available for biochemical analysis. The
strong association between the latter and tumour stage, tumour
size (clinical/pathological) and tumour grade is expected, since
the larger tumours were more likely to yield a larger tumour
sample for biochemical analysis. These multiple interassocia-
tions highlight the need for a multivariate analysis in
determining key prognostic factors, as demonstrated below.
Clinical outcome
After a median follow-up of 36.2 months, (range 24.8-46.5
months), there had been 55 recurrences and 35 deaths.
Eighteen (33%) of the recurrences were locoregional only.
Relationship of the four biochemical markers and other factors
to clinical outcome
When the data for each biochemical marker were divided into
quartiles and examined by life-table analysis with respect to
disease-free interval (Figure 2a) or overall survival (Figure
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Figure 1 The inter-relationships between the four biochemical
markers studied in 215 patients with operable breast cancer. The
Spearman rank correlation coefficients were -0.26 (P=0.001) for
log ER vs log EGFR; + 0.14 (P= 0.036) for c-AMP-b vs log ER;
and +0.32 (P=0.0001) for c-AMP-b vs cath D.
2b), only ER measurements showed a clear relationship to
risk of recurrence or survival: patients with ER concentra-
tions in excess of 164 fmol mg-I protein (group 4) had a very
good prognosis, those with ER< 11 fmol mg-I protein
(group 1) had a very poor prognosis and those with
intermediate levels (groups 2 and 3) had an intermediate
prognosis (Figure 2a and b). By contrast, there was no clear
relationship between the likelihood of recurrence and levels of
the other three biochemical markers.
Similarly, life-table analysis was carried out for three other
characteristics of the patients - clinical tumour size, tumour
grade and node status. The resulting survival curves are
shown in Figures 3a and b.
Relationship of biochemical and clinicalfactors to prognosis by
Cox's proportional hazards model analysis
Eighteen variables were examined in relation to clinical
outcome, each in univariate and multivariate analyses.
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After a median follow-up of 36 months, the data were
analysed separately for total recurrences (n= 55), distant
recurrences (n= 37), locoregional recurrences only (n= 18)
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and deaths (n = 35); the results are recorded in Tables II,
III, IV and V. By univariate analysis, 10 of the 18 factors
examined [ER concentration, node status, tumour grade,
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tumour type, soluble protein content, type of surgery,
tumour stage, type of systemic therapy and tumour size
(clinical/pathological)] appeared to relate to risk of any
recurrence (Table II). Eight of these factors (all save
tumour stage and tumour type) also appeared to relate by
univariate analysis to risk of distant metastases (Table III),
and seven (ER concentration, node status, tumour grade,
clinical and pathological tumour size, type of surgery and
soluble protein content) appeared to relate to risk of death
(Table V). For risk of local recurrence, however, only
tumour grade and ER concentration appeared important
(Table IV).
By multivariate analysis, ER concentration, node status
and tumour grade related to risk of total recurrences or
distant metastases and for the latter, clinical tumour size also
proved to be of independent prognostic value, although at a
less significant level (P=0.032). Only ER concentration and
node status related to risk of death, but for local recurrence,
tumour grade alone was of prognostic value.
The relative importance of the four key factors found to
be of prognostic significance, examined simultaneously
(compare the above stepwise statistical procedure), is shown
in Table VI.
These results demonstrate that for an increase in tumour
grade of 1, there is an increased risk of all recurrences or
death ranging from approximately 1.5- to 2.5-fold. Similarly,
for every 1 cm increase in clinical tumour size, there is a 1.1-
to 1.2-fold increase in risk of distant recurrence or death,
while for node involvement, the risk is increased 1.6- to 2.5-
fold for all recurrences or death. Conversely, each doubling
of ER concentration is associated with a consistent reduction
of risk of approximately 20% across the board, i.e. for local,
distant, any recurrence and death.
Discussion
This study set out to identify biochemical markers of value in
gauging prognosis in operable breast cancer. In several
previous studies (Humeniuk et al., 1982; Hawkins et al.,
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Table II Relationship of biochemical, clinical and other factors to
likelihood of any recurrence after a median follow up of 36 months
P-value
Factor Univariate Multivariate
ERa <0.0001 < 0.0001
T grade <0.0001 0.004
N status 0.0007 0.005
T size (pathological) <0.0001 0.46
T size (clinical) 0.0002 0.082
Soluble protein g-1 0.0046 0.92
Type surgery 0.0047 0.40
T stage 0.016 0.16
T histopathological type 0.026 0.13
Systemic therapy 0.048 0.46
Radiotherapy 0.073 0.90
Cathepsin Da 0.095 0.22
EGFRa 0.095 0.52
Membrane protein g-1 0.13 0.27
Tissue weight 0.16 0.59
c-AMP-b 0.63 0.88
Age 0.77 0.53
Menstrual status 0.89 0.57
aLogarithm used.
Table III Relationship of biochemical, clinical and other factors to
likelihood of distant recurrence after 36 months
P-value
Factor Univariate Multivariate
ERa < 0.0001 < 0.0002
N status 0.0006 0.017
T grade <0.0001 0.018
T size (clinical) 0.0001 0.032
T size (pathological) <0.0001 0.88
Type surgery 0.0022 0.88
Soluble protein g-1 0.011 0.86
Systemic therapy 0.042 0.43
T histopathological type 0.052 0.18
Membrane protein g-1 0.077 0.37
Radiotherapy 0.13 0.46
T stage 0.15 0.29
Cathepsin Da 0.16 0.18
Age 0.20 0.88
Tissue weight 0.29 0.87
EGFRa 0.36 0.14
c-AMP-b 0.40 0.45
Menstrual status 0.45 0.91
aLogarithm used.
Table IV Relationship of biochemical, clinical and other factors to
likelihood of local recurrence after 36 months
P-value
Factor Univariate Multivariate
T grade 0.003 0.003
ERa 0.01 0.12
T stage 0.08 0.14
Soluble protein g7l 0.08 0.96
T size (pathological) 0.09 0.39
Systemic therapy 0.11 0.18
T histopathological type 0.12 0.44
Tissue weight 0.13 0.24
N status 0.13 0.59
Age 0.18 0.32
EGFRa 0.22 0.44
T size (clinical) 0.36 0.83
Menstrual status 0.51 0.73
Type surgery 0.58 0.42
Cathepsin Da 0.68 0.69
c-AMP-b 0.85 0.26
Radiotherapy 0.89 0.74
Membrane protein g-1 0.97 0.19
aLogarithm used.
Table V Relationship of biochemical, clinical and other factors to
likelihood of death after 36 months
P-value
Factor Univariate Multivariate
ERa < 0.0001 < 0.0001
N status 0.0008 0.0005
T grade 0.0005 0.17
T size (clinical) 0.0023 0.15
T size (pathological) 0.0089 0.73
Soluble protein g7l 0.026 0.40
Type surgery 0.022 0.53
Cathepsin Da 0.11 0.082
T histopathological type 0.11 0.42
Membrane protein g-1 0.16 0.84
Radiotherapy 0.17 0.85
Age 0.19 0.14
Systemic therapy 0.26 0.58
T stage 0.27 0.88
Tissue weight 0.29 0.53
EGFRa 0.45 0.42
Menstrual status 0.75 0.39
c-AMP-b 0.84 0.72
aLogarithm used.
Table VI The relative importance of the four key prognostic factors
in 215 patients with operable breast cancer (hazard ratios and 95%
confidence limits)
Local Distant Any
Variablea recurrence recurrence recurrence Death
ER 0.84 0.76 0.79 0.75
(0.68- 1.02) (0.65-0.88) (0.69-0.90) (0.64-0.89)
Grade 2.57 2.09 2.06 1.50
(1.10 -5.99) (1.14- 3.83) (1.22 -3.48) (0.78 -2.87)
Tumour size 0.95 1.21 1.16 1.13
(0.68- 1.32) (1.02- 1.44) (0.98- 1.37) (0.93- 1.39)
Node status 1.69 2.26 2.01 2.49
(0.63-4.57) (1.19-4.33) (1.12-3.63) (1.19-5.19)
aHazard ratios calculated for an increase of 0.693 in log ER
(doubling concentration), per category increase in grade, for 1 cm
increase in clinical size of tumour, and node-positive vs node-negative.
1987a, 1991), it was evident that ER measurements were of
prognostic value and, thus, while it seemed likely that ER
might be of value, it was hoped to detect other markers,
which would be of greater, additional benefit.
Of the markers studied, cathepsin D and cyclic AMP
binding were inter-related. To our knowledge, this relation-
ship has not been reported previously; its significance is
uncertain. Whereas cyclic AMP-binding proteins are found in
both cytoplasm and nucleus of tumour and other cells (Cho-
Chung et al., 1978), cathepsin D is a lysosomal enzyme of
both tumour cells and macrophages (Henry et al., 1990;
O'Donoghue et al., 1992; Stonelake et al., 1994). Cyclic
AMP-binding has also been detected in macrophages
(Yamamoto et al., 1987) and it may be that the inter-
relationship between cathepsin D and cyclic AMP-finding
relates to this. A weaker association was found between cyclic
AMP-binding protein(s) and ER concentration, and this
might simply reflect the fact that more cellular tumour
specimens yield both more ER (when positive) and more
cyclic AMP-binding protein(s). As has been shown previously
in many other studies including our own, there was a
significant inverse relationship between ER and EGFR.
After a median follow-up of 3 years, for risk of either any
recurrence or death, ER concentration, node status and
tumour grade remained the only significant independent
factors among those examined. For risk of distant
recurrence, clinical tumour size made a slight additional
contribution. For risk of local recurrence, a risk generally
associated with certain histopathological features (Paterson et
al., 1992), only tumour grade was important by multivariate
1
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stepwise analysis, although grade was not reported in that
earlier study. It should be noted that in the present study,
however, there were relatively few local recurrences and,
therefore, the power to identify significant prognostic factors
is limited. These findings are in line with those of our
previous report (Hawkins et al., 1991) in a different,
heterogeneous group of patients (n = 123) of poorer prog-
nosis, presenting at eleven different hospitals rather than at a
single Breast Unit. The finding that tumour grade was of
strong prognostic significance is in agreement with the results
of multiple studies from other centres, particularly the
Nottingham group e.g. Haybittle et al. (1982), plus one of
our own earlier studies (Hawkins et al., 1987a). Cytosolic
protein concentration, reported previously by Soreide et al.
(1991) to be of some prognostic value, was found to be of
significance here only in a univariate analysis; its value
disappeared on multivariate analysis.
In the present work, neither cathepsin D nor cyclic AMP-
binding proteins were found to be of significance in
influencing disease-free interval. This was unexpected in the
light of previous work. High levels of cathepsin D have been
shown to be associated with a poorer prognosis in most
(Rochefort et al., 1990), but not all (e.g. Henry et al., 1990;
Stonelake et al., 1994), previous studies. However, two recent
histochemical studies (Castiglioni et al., 1994; Roger et al.,
1994) have confirmed the complexity of the situation, in that
cathepsin D is not confined to malignant cells and Cardiff
(1994), in an associated editorial, cites methodology and type
of antibody used as potentially confounding factors. Johnson
et al. (1993) demonstrated that, in cell lines, cathepsin D is
not correlated with invasiveness, reinforcing the view that the
prognostic role of cathepsin D probably relates to high levels
of cathepsin D in stromal components such as infiltrating
inflammatory cells, although Stonelake et al. (1994) consider
that tumour aggressiveness/more advanced disease may be
associated with concomitant increased expression of cathe-
psin D by both malignant epithelial cells and macrophages.
It may be that similar considerations apply to cyclic AMP-
binding proteins, i.e. that these, too, being found in both
tumour cells and macrophages (Yamamoto et al., 1987), may
reflect the degree of inflammation in the tumour, rendering
high levels of these proteins a sign of poor prognosis. In a
previous, retrospective study (Miller et al., 1990), we have
found that patients with high levels of cyclic AMP binding
had a very short disease-free survival, this finding being
confirmed in a second, prospective study (Miller et al., 1993).
Careful comparison of these previous studies with the present
work shows some changes over the years during which the
studies were conducted: 1979-84 (Miller et al., 1990); 1984-
87 (Miller et al., 1993); and 1990-91 (present work). There
have been changes in (1) the proportion of patients available
for study from the whole population attending our Breast
Clinic (12%, 15% and 33% respectively in the references
Miller et al., 1990; Miller et al., 1993 and the present work);
(2) the proportion of patients studied who had high levels
(>8000 fmol mg-' protein) of cyclic AMP-binding in their
tumours (12%, 9% and 3% respectively); and (3) the
proportion of patients studied who received adjuvant or
primary endocrine therapy (40%, 67% and 80% respec-
tively). Thus, the most likely explanations for the differences
between the present and earlier studies are that: (1) here,
follow-up is relatively short (median 36.2 months); (2) the
patient population (approximately 33% of those presenting
to our Unit) differs from those previously examined, which
tended to include patients with larger tumours, higher levels
of cyclic AMP-binding proteins and poorer prognosis; (3) a
large proportion (80%) of the present study group of patients
received adjuvant or primary endocrine therapy, mostly
tamoxifen, which may have increased the apparent impor-
tance of ER concentration in influencing outcome; (4) it
should be noted that in the present study, we have analysed
ER concentration as a continuous variable. Despite the
recommendation of statisticians, e.g. Altman (1991), Simon et
al. (1994) to do this, a very large number of studies continue
to classify ER as a dichotomous variable (+ or -) using an
arbitrary cut-off and find ER of little prognostic value. Use
of an inappropriate cut-off can destroy the value of almost
any prognostic factor.
The quantitative importance of ER measurements found
here (quartiles <11. 11-64, 64 -164 and >164fmolmg-'
protein) is in agreement with the views of Shek and Godolphin
(1989) who, in a larger series of patients (1184), found marked
differences for patients with <1, 2-9, 10-159 and
> 160 fmol mg-' protein. The most useful prognostic factors
are likely to change with the course of the disease and, thus,
follow-up time may be critical in relation to the prognostic
power of a given factor; in the extreme case, for example, as
Stoll (1992) has pointed out, any factors which have
prognostic significance initially at presentation may have less
value after relapse and the initial list of prognostic indices to
be considered may well require revision at that event. In the
present work, analyses at two time points (16.5 months and
36.2 months) have shown little change; only tumour size has
become of significance for risk of recurrence at a distant site
after 3 years. However, in the light of Stoll's comments, we
propose to update our study after further follow-up.
The present study found no evidence that EGFR
measurements offer prognostic information additional to
that provided by ER concentration, node status and tumour
grade. These findings are also in line with our previous study
(Hawkins et al., 1991) and the results of multivariate analyses
by Dutch workers (Koenders et al., 1993; Foekens et al.,
1989) and may perhaps relate to factors other than the four
listed above. In the present study, in order to be able to
include as many tumours (irrespective of size) as possible, we
changed our method for EGFR assay from a multiple-dose
one with Scatchard analysis (Hawkins et al., 1991) to a single
saturating-dose assay. Neither method, in our experience, is
ideal, and concern has been expressed over the methodology
of this assay (Koenders et al., 1992). However, two other
considerations may be of greater significance, as discussed
previously (Hawkins, 1993). Firstly, there is a strong inverse
relationship between ER and EGFR measurements and,
where the former are satisfactory, they may enter the Cox
statistical model first and eliminate a contribution from the
latter. Secondly, there appears to be no clear difference
between EGFR levels in benign and malignant breast tissues
(compare EGFR levels in benign tissues 0-5.11 fmol mg-'
membrane protein, n = 18, and malignant tissues which, with
the exception of three tumours, were all in the range 0-
6.43 fmol mg-' membrane protein, n = 215; see Methods
section and Barker et al., 1989; Dittadi et al., 1993),
rendering more significant the possible contribution of any
benign material homogenised in the 'tumour' specimen
(compare ER levels in benign tissues 2-102 fmol mg-'
protein, n = 18, and malignant tissues 0- 1511 fmol mg-'
protein, n = 2600, unpublished observations.).
In summary, we have shown that patients with operable
breast cancer are at increased risk of recurrence within 1 -3
years when ER-negative and/or node-positive and/or of low
tumour grade; this recurrence being most likely to be at a
distant site.
It is concluded that in the early follow-up period, ER
concentration is of perhaps greater prognostic significance
than is generally appreciated, especially when measured with
careful quality control of both assay and tumour specimen;
other biochemical factors of larger/additional prognostic
significance remain to be established.
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